Pitavastatin (Calcium)

Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects[1][2][3][8].

Product Specifications

CAS Number

[147526-32-7]

Product Name Alternative

NK-104 (hemicalcium) ; Pitavastatin (hemicalcium)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Autophagy; HMG-CoA Reductase (HMGCR) ; Mitophagy

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer; Metabolic Disease; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/pitavastatin-calcium.html

Purity

99.89

Solubility

DMSO : ≥ 50 mg/mL

Smiles

O=C([O-])C[C@H](O)C[C@H](O)/C=C/C1=C(C2=CC=C(F)C=C2)C3=CC=CC=C3N=C1C4CC4.[0.5Ca2+]

Molecular Formula

C25H23FNO4.1/2Ca

Molecular Weight

440.49

Precautions

H302, H315, H319, H335

References & Citations

[1]Mukhtar RY, et al. Pitavastatin. Int J Clin Pract. 2005 Feb;59 (2) :239-52.|[2]Kajinami K, et al. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 2003 Fall;21 (3) :199-215.|[3]Tajiri K, et al. Pitavastatin regulates helper T-cell differentiation and ameliorates autoimmune myocarditis in mice. Cardiovasc Drugs Ther. 2013 Oct;27 (5) :413-24.|[4]Hamano T, et al. Pitavastatin decreases tau levels via the inactivation of Rho/ROCK. Neurobiol Aging. 2012 Oct;33 (10) :2306-20.|[5]de Wolf E, et al.Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer.Sci Rep. 2017 Jul 14;7 (1) :5410.|[6]Demir B, et al. The Effects of Pitavastatin on Nuclear Factor-Kappa B and ICAM-1 in Human Saphenous Vein Graft Endothelial Culture. Cardiovasc Ther. 2019 May 2;2019:2549432.|[7]Hayashi T, et al. A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits. Atherosclerosis. 2004 Oct;176 (2) :255-63.|[8]Sahebkar A, et al. A comprehensive review on the lipid and pleiotropic effects of pitavastatin. Prog Lipid Res. 2021 Nov;84:101127.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture and light)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

Acta Biochim Biophys Sin (Shanghai) . 2024 Apr 25;56 (4) :621-633.|Antioxidants (Basel) . 2024 May 29;13 (6) :667.|Bioorg Chem. 2024 Jun:147:107369.|Research Square Preprint. 2024 Apr 9.|Sci Data. 2024 Sep 19;11 (1) :1024.|Acta Biochim Biophys Sin (Shanghai) . 2024 Apr 25;56 (4) :621-633.|Acta Pharm Sin B. 2020 May;10 (5) :850-860.|Biochem Pharmacol. 2019 Nov:169:113612.|bioRxiv. 2024 June 11.|Braz J Med Biol Res. 2025 Aug 22:58:e14540.|J Hepatol. 2021 Aug;75 (2) :363-376.|Proteomics. 2023 Aug;23 (16) :e2300041.